Emergent Biosolutions Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Emergent Biosolutions Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 4.50 $ to 13.90 $ · Last price: 7.00 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Drug Manufacturers - Specialty & Generic
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc EBS | 0.4 | – | 5.2 | 50.4 | – | -28.8 | -9.9 |
| Takeda Pharmaceutical Co Ltd TAK | 60.9 | – | 23.2 | 64.5 | 16.5 | 4.3 | 28.2 |
| Teva Pharma Industries Ltd TEVA | 45.7 | 65.3 | 17.8 | 52.5 | 4.0 | 4.3 | 106.3 |
| Zoetis Inc ZTS | 30.8 | 12.2 | 9.5 | 71.7 | 36.6 | 2.3 | -49.5 |
| United Therapeutics Corporation UTHR | 21.1 | 18.0 | 11.0 | 86.1 | 41.7 | 10.6 | 23.2 |
| Viatris Inc VTRS | 19.4 | – | 11.9 | 40.3 | 6.8 | -3.0 | 84.4 |
| Neurocrine Biosciences Inc NBIX | 15.3 | 24.1 | 17.4 | 64.5 | 22.8 | 21.5 | 6.4 |
| Elanco Animal Health ELAN | 11.3 | – | 19.3 | 55.4 | 12.3 | 6.2 | 23.4 |
| Dr. Reddy’s Laboratories Ltd RDY | 10.1 | 28.9 | 14.2 | 50.2 | 4.3 | 8.6 | -19.9 |
| Median of companies shown | 19.4 | 24.1 | 14.2 | 55.4 | 14.4 | 4.3 | 23.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 489 | 106 | 52 | 1.05 | 53 | 596 | 970 |
| 2017 | 561 | 124 | 83 | 1.64 | 208 | 912 | 1,070 |
| 2018 | 782 | 90 | 63 | 1.22 | 42 | 1,011 | 2,229 |
| 2019 | 1,106 | 114 | 55 | 1.04 | 188 | 1,089 | 2,327 |
| 2020 | 1,577 | 439 | 306 | 5.68 | 537 | 1,447 | 2,883 |
| 2021 | 1,774 | 341 | 220 | 4.06 | 321 | 1,612 | 2,958 |
| 2022 | 1,118 | -170 | -212 | -4.22 | -34 | 1,388 | 3,166 |
| 2023 | 1,049 | -726 | -761 | -14.85 | -206 | 649 | 1,823 |
| 2024 | 1,044 | -109 | -191 | -3.60 | 59 | 483 | 1,390 |
| 2025 | 743 | 110 | 53 | 0.93 | 171 | 523 | 1,319 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.58 | – | 195 | -29.60 | -16.10 | -80 | -82 |
| 2025: Q1 | 1.19 | 588.30 | 222 | -26.00 | 30.60 | -11 | -15 |
| 2025: Q2 | -0.22 | – | 141 | -44.70 | -8.50 | 106 | 104 |
| 2025: Q3 | 0.91 | -56.10 | 231 | -21.30 | 22.20 | -2 | -6 |
| 2025: Q4 | -0.96 | – | 149 | -23.60 | -36.70 | 78 | 74 |
| 2026: Q1 | 0.07 | -94.10 | 156 | -29.70 | 4.40 | -34 | -36 |
| 2026: Q2 | -3.49 | -1,486.40 | 234 | 66.30 | -76.90 | 56 | 54 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.36 | 0.36 – 0.36 | 657 | -76.5% | 2 |
| 12/31/2027 | 1.05 | 1.05 – 1.05 | 703 | 191.0% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly -15.1% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $85.9M |
|---|---|
| Market cap | $356.0M |
| Free cash flow in year ten | $16.6M |
| Terminal value as a share of market value | 24.6% |
For comparison: over the past five years free cash flow shrank by 16.9% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -12.7%
- More than 10% revenue growth is expected for the coming year 21.7%
- Share count grows by less than 3% a year 4.2%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -7.7%
- Gross margin at 40% or higher and without meaningful erosion 47.2%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 1.5 x EBITDA
- Operating cash flow covers the profits of the last three years 922 m
- Return on capital at 15% or higher, or up versus two years ago 9.3%
- Insiders hold at least 10% or are net buyers 3.9%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 4.8%
- Exp. sales growth 3Y > 5% -2.7%
- EBIT growth 10Y > 5% 0.5%
- Exp. EBIT growth 3Y > 5% 6.2%
- Net debt < 4x EBIT 3.3x
- EBIT positive, 10Y straight 7
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% 61.1%
- ROCE > 15% 9.3%
- Expected return > 10% 53.0%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Emergent BioSolutions Inc., ein Life-Sciences-Unternehmen, bietet Lösungen zur Vorsorge und Reaktion auf versehentliche, vorsätzliche und natürlich auftretende Bedrohungen der öffentlichen Gesundheit in den USA, Kanada und international an.
- Employees
- 900
- Headquarters
- Gaithersburg, MD
- Address
- 300 Professional Drive, 20879 Gaithersburg, United States
- Phone
- 240 631 3200
- Website
- emergentbiosolutions.com
- IPO Date
- 11/15/2006
- ISIN
- US29089Q1058
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph C. Papa Jr., M.B.A., R.Ph. | CEO, President & Director | 1956 |
| Richard S. Lindahl M.B.A. | Executive VP & CFO | 1964 |
| Coleen Glessner | Executive Vice President of Quality, Ethics & Compliance | 1971 |
| Paul A. Williams | Senior Vice President of Products Business | 1967 |
| Jessica Perl | Senior VP, Corporate Secretary & General Counsel | 1981 |
| Assal Hellmer | Vice President of Communications | – |
| Michelle Pepin | Senior VP & Chief Human Resource Officer | – |
| Stephanie Duatschek | Executive VP & Chief Growth Officer | – |
| William Hartzel | Senior Vice President of Manufacturing & Bioservices | 1978 |
| Frank Vargo | VP & Treasurer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 09/14/2026 Emergent BioSolutions Inc. (EBS): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 09/01/2026 Emergent BioSolutions Inc. (EBS): Other Events; Financial Statements and Exhibits SEC ↗
- 08/05/2026 Emergent BioSolutions Inc. (EBS): Results of Operations and Financial Condition; Cost Associated with Exit or Disposal Activities; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.